Adrian Marino-Enriquez

List of Publications by Year
in descending order

48 papers	2,729 citations	236612 25 h-index	288905 40 g-index
49 all docs	49 docs citations	49 times ranked	3162 citing authors

#	Article	IF	Citations
1	Epithelioid Inflammatory Myofibroblastic Sarcoma. American Journal of Surgical Pathology, 2011, 35, 135-144.	2.1	309
2	The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas. American Journal of Surgical Pathology, 2012, 36, 641-653.	2.1	265
3	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 929-934.	3.3	239
4	Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma With YWHAE-FAM22 Rearrangement. American Journal of Surgical Pathology, 2012, 36, 1562-1570.	2.1	184
5	Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics, 2014, 46, 601-606.	9.4	142
6	Dedifferentiated Liposarcoma With â€œHomologousâ€•Lipoblastic (Pleomorphic Liposarcoma-like) Differentiation: Clinicopathologic and Molecular Analysis of a Series Suggesting Revised Diagnostic Criteria. American Journal of Surgical Pathology, 2010, 34, 1122-1131.	2.1	134
7	ALK rearrangement in sickle cell traitâ€associated renal medullary carcinoma. Genes Chromosomes and Cancer, 2011, 50, 146-153.	1.5	133
8	BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas. American Journal of Surgical Pathology, 2018, 42, 335-341.	2.1	118
9	ALK rearrangement and overexpression in epithelioid fibrous histiocytoma. Modern Pathology, 2015, 28, 904-912.	2.9	110
10	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. British Journal of Cancer, 2019, 120, 612-620.	2.9	109
11	VCL-ALK Renal Cell Carcinoma in Children With Sickle-cell Trait. American Journal of Surgical Pathology, 2014, 38, 858-863.	2.1	84
12	Angiofibroma of Soft Tissue. American Journal of Surgical Pathology, 2012, 36, 500-508.	2.1	80
13	Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement. Modern Pathology, 2014, 27, 751-757.	2.9	71
14	Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors. Molecular Cancer Therapeutics, 2012, 11, 1770-1780.	1.9	67
15	Alternate <scp>PAX</scp>3â€<scp>FOXO</scp>1 oncogenic fusion in biphenotypic sinonasal sarcoma. Genes Chromosomes and Cancer, 2016, 55, 25-29.	1.5	67
16	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature Communications, 2017, 8, 14674.	5.8	53
17	Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Modern Pathology, 2021, 34, 95-103.	2.9	52
18	ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genetics, 2013, 206, 357-373.	0.2	51

#	Article	IF	Citations
19	KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. Journal of Clinical Oncology, 2015, 33, e93-e96.	0.8	48
20	CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. Molecular Cancer Therapeutics, 2015, 14, 1346-1353.	1.9	44
21	<scp>ALK</scp>â€rearranged renal cell carcinomas in children. Genes Chromosomes and Cancer, 2016, 55, 442-451.	1.5	43
22	Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surgical Pathology Clinics, 2016, 9, 457-473.	0.7	42
23	Shouldn't we care about the biology of benign tumours?. Nature Reviews Cancer, 2014, 14, 701-702.	12.8	40
24	Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line. Laboratory Investigation, 2016, 96, 1128-1137.	1.7	31
25	NR4A3 Immunohistochemistry Reliably Discriminates Acinic Cell Carcinoma from Mimics. Head and Neck Pathology, 2021, 15, 425-432.	1.3	28
26	Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1. JCO Precision Oncology, 2020, 4, 79-90.	1.5	27
27	KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors â€" TORC1/2 Inhibition as Salvage Strategy. Molecular Cancer Therapeutics, 2019, 18, 1985-1996.	1.9	22
28	Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib. Oncotarget, 0, 7, 41390-41403.	0.8	22
29	Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene, 2019, 38, 6615-6629.	2.6	21
30	Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. Cancer, 2021, 127, 2666-2673.	2.0	15
31	Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications. Surgical Pathology Clinics, 2015, 8, 525-537.	0.7	14
32	Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy. British Journal of Cancer, 2016, 114, 1219-1226.	2.9	13
33	YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways. Oncogenesis, 2021, 10, 37.	2.1	11
34	The utility and limitation of single nucleotide polymorphism analysis on whole genome amplified mesenchymal tumour DNA in formalin fixed tumour samples. Pathology, 2012, 44, 33-41.	0.3	9
35	Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes. Modern Pathology, 2021, 34, 1763-1779.	2.9	8
36	Conjoined hyperactivation of the RAS and PI3K pathways in advanced GIST.. Journal of Clinical Oncology, 2016, 34, e22520-e22520.	0.8	7

#	Article	IF	Citations
37	Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours. British Journal of Cancer, 2020, 122, 372-381.	2.9	5
38	Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.. Journal of Clinical Oncology, 2022, 40, 11509-11509.	0.8	3
39	Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2018, 36, 11510-11510.	0.8	1
40	Molecular characterization and management of secondary resistance to serial TRK inhibitors.. Journal of Clinical Oncology, 2019, 37, e22547-e22547.	0.8	1
41	Abstract 290: NF1 loss modulates cellular fitness in KIT-mutant gastrointestinal stromal tumor (GIST). , 2016, , .		1
42	In Response to â€œReexamining the molecular findings in specialized stromal tumors of the prostateâ€• Modern Pathology, 2021, 34, 2082-2083.	2.9	0
43	Abstract 1572: Dystrophin Is a tumor suppressor in human cancers with myogenic programs. , 2014, , .		0
44	Abstract 607: Genomic analyses and novel models validate CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans. , 2015, , .		0
45	Abstract B16: Dystrophin is a tumor suppressor in peripheral nerve sheath tumors. , 2018, , .		0
46	The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received.. Journal of Clinical Oncology, 2018, 36, 1054-1054.	0.8	0
47	Kidney: ALK-rearranged renal cell carcinoma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018, , .	0.1	0
48	Abstract 5648: Response and resistance to CDK2 and CDK4/6 inhibition in GIST. Cancer Research, 2022, 82, 5648-5648.	0.4	0